These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31009931)

  • 21. [Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis].
    Boyko AN; Alifirova VM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):135-139. PubMed ID: 29265099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upregulation of TRAIL expression on human T lymphocytes by interferon beta and glatiramer acetate.
    Arbour N; Rastikerdar E; McCrea E; Lapierre Y; Dörr J; Bar-Or A; Antel JP
    Mult Scler; 2005 Dec; 11(6):652-7. PubMed ID: 16320724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients.
    Rovituso DM; Duffy CE; Schroeter M; Kaiser CC; Kleinschnitz C; Bayas A; Elsner R; Kuerten S
    Sci Rep; 2015 Sep; 5():14265. PubMed ID: 26387426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
    Río J; Rovira A; Tintoré M; Sastre-Garriga J; Castilló J; Auger C; Nos C; Comabella M; Tur C; Vidal Á; Montalbán X
    Mult Scler; 2014 Oct; 20(12):1602-8. PubMed ID: 24622350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study.
    Jongen PJ; Lehnick D; Sanders E; Seeldrayers P; Fredrikson S; Andersson M; Speck J;
    Health Qual Life Outcomes; 2010 Nov; 8():133. PubMed ID: 21078142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b.
    Jensen MA; Yanowitch RN; Reder AT; White DM; Arnason BG
    Mult Scler; 2010 Jan; 16(1):30-8. PubMed ID: 20007427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Satisfaction and practicality of a prefilled glatiramer acetate pen in relapsing-remitting multiple sclerosis patients.
    Schreiber H; Hipp J; Roßnagel F; Moritz C
    Neurodegener Dis Manag; 2023 Oct; 13(5):281-288. PubMed ID: 37909320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients.
    Ziemssen T; Calabrese P; Penner IK; Apfel R
    J Neurol; 2016 Apr; 263(4):784-91. PubMed ID: 26914926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
    Sellner J; Koczi W; Harrer A; Oppermann K; Obregon-Castrillo E; Pilz G; Wipfler P; Afazel S; Haschke-Becher E; Trinka E; Kraus J
    Clin Exp Immunol; 2013 Sep; 173(3):381-9. PubMed ID: 23611040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
    Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
    Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis.
    Dhib-Jalbut S; Chen M; Henschel K; Ford D; Costello K; Panitch H
    Mult Scler; 2002 Dec; 8(6):485-91. PubMed ID: 12474988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial.
    Ozakbas S; Cinar BP; Kosehasanoğullari G; Kahraman T; Oz D; Kursun BB
    Clin Neurol Neurosurg; 2017 Sep; 160():69-72. PubMed ID: 28689102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.
    Zivadinov R; Bergsland N; Hagemeier J; Tavazzi E; Ramasamy DP; Durfee J; Cherneva M; Carl E; Carl J; Kolb C; Hojnacki D; Weinstock-Guttman B
    J Neurol Sci; 2018 Apr; 387():152-156. PubMed ID: 29571854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry.
    Spelman T; Frisell T; Piehl F; Hillert J
    Mult Scler; 2018 Jul; 24(8):1087-1095. PubMed ID: 28649912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients.
    Berthelot L; Miqueu P; Pettré S; Guillet M; Moynard J; Wiertlewski S; Lefrère F; Brouard S; Soulillou JP; Laplaud DA
    Clin Immunol; 2010 Apr; 135(1):33-42. PubMed ID: 20116333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefit of endermology on indurations and panniculitis/lipoatrophy during relapsing-remitting multiple sclerosis long-term treatment with glatiramer acetate.
    Márquez-Rebollo C; Vergara-Carrasco L; Díaz-Navarro R; Rubio-Fernández D; Francoli-Martínez P; Sánchez-De la Rosa R
    Adv Ther; 2014 Aug; 31(8):904-14. PubMed ID: 25047757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of immunomodulatory therapy with interferon-β or glatiramer acetate on multiple sclerosis-associated uveitis.
    Velazquez-Villoria D; Macia-Badia C; Segura-García A; Pastor Idoate S; Arcos-Algaba G; Velez-Escola L; García-Arumí J
    Arch Soc Esp Oftalmol; 2017 Jun; 92(6):273-279. PubMed ID: 28188020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.